Department of Infectious Diseases, the First Affiliated Hospital of Wannan Medical College, Wuhu 241000, China.
Department of Infectious Diseases, the First Hospital of Quanzhou, Fujian Medical University, Quanzhou 362000, China.
Int J Infect Dis. 2021 Sep;110:204-212. doi: 10.1016/j.ijid.2021.07.061. Epub 2021 Jul 29.
Our study aimed to evaluate the correlation between the sensitivity of adenosine deaminase (ADA) testing for the diagnosis of tuberculous peritonitis (TBP) and patient age or cirrhosis status.
Clinical data for patients clinically diagnosed with TPB (n = 132) or not (n = 147) were assessed. ADA activity was compared among three age groups (< 45 yr, 45-60 yr, and ≥ 60 yr) and among cirrhosis-related subgroups. Cut-off values for the ADA test were analyzed among three patient populations (young non-cirrhotic, n = 97; older non-cirrhotic, n = 115; cirrhotic, n = 67), and validated in a cohort of 259 participants.
According to the multivariate regression analyses, age < 45 yr is highly predictive of TBP risk. The young non-cirrhotic TBP patients had higher ADA activity than the middle-aged or old controls (p < 0.01). Significantly decreased activity and efficacy of ADA were observed in the cirrhotic subgroup/population, regardless of age or cohort. For the above-mentioned two non-cirrhotic populations in the validation cohort, the ADA test showed excellent performance using thresholds of 30.5 IU/L and 20.5 IU/L, with respective sensitivities of 91.1% and 92.6%.
ADA activity is negatively associated with increasing age and underlying cirrhosis. Optimizing cut-off values for the ADA test can increase its sensitivity in non-cirrhotic individuals older than 45 years.
本研究旨在评估腺苷脱氨酶(ADA)检测对结核性腹膜炎(TBP)诊断的敏感性与患者年龄或肝硬化状态之间的相关性。
评估了临床诊断为 TBP(n=132)或未诊断为 TBP(n=147)的患者的临床数据。比较了三个年龄组(<45 岁、45-60 岁和≥60 岁)和与肝硬化相关的亚组之间的 ADA 活性。在三个患者人群中(年轻非肝硬化组,n=97;年龄较大非肝硬化组,n=115;肝硬化组,n=67)分析 ADA 检测的截止值,并在 259 名参与者的队列中进行验证。
根据多变量回归分析,年龄<45 岁是 TBP 风险的高度预测因素。年轻的非肝硬化性 TBP 患者的 ADA 活性高于中年或老年对照组(p<0.01)。无论年龄或队列如何,在肝硬化亚组/人群中均观察到 ADA 活性显著降低和疗效降低。对于验证队列中的上述两个非肝硬化人群,ADA 检测使用 30.5 IU/L 和 20.5 IU/L 的阈值表现出优异的性能,相应的敏感性分别为 91.1%和 92.6%。
ADA 活性与年龄增加和潜在肝硬化呈负相关。优化 ADA 检测的截止值可以提高 45 岁以上非肝硬化个体的敏感性。